Fenton, R T <br/><br/>
A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401.  [electronic resource] 

 -  Human gene therapy  Jan 1995 
 - 87-106 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1043-0342 
<br/><br/><label>Standard No.: </label>10.1089/hum.1995.6.1-87  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, Neoplasm--immunology<br/>Clinical Protocols<br/>Female<br/>Genetic Therapy<br/>HLA-A1 Antigen--immunology<br/>HLA-A2 Antigen--immunology<br/>Humans<br/>Immunity, Cellular--genetics<br/>Male<br/>Melanoma--genetics<br/>Middle Aged<br/>Transfection<br/>Tumor Cells, Cultured